Previsão

O preço-alvo médio dos analistas é € 71,25 (+43,94%). A mediana é € 59,24 (+19,68%).

Comprar
  7
Manter
  2
Vender
  1

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Liquidia ends patent dispute with United Therapeutics and secures market access for Yutrepia

    Liquidia has entered into a global settlement agreement with United Therapeutics, thereby ending all patent litigation. Supply of PAH patients with the dry‑powder formulation Yutrepia remains fully uninterrupted. Liquidia will not appeal and has removed the PH-ILD indication from the product information. » Mais em finanzen.net


  • Liquidia reports strong YUTREPIA growth, pipeline expansion and positive profitability

    Liquidia said at the Wells Fargo Healthcare Conference that YUTREPIA generated $170 million in revenue in Q2 2026 and that quarterly sales have increased by about $40 million in each of the past three quarters. About 75% of prescriptions are for treatment‑naive patients, and the company reported EBITDA of roughly $100 million, net income of about $80 million and an additional $60 million of cash flow in the quarter. Liquidia is expanding its commercial and clinical programs with 8–10 planned studies in the next 12 months, plans L606 as a follow‑on program, expects long‑term revenue above $1 billion, but faces an outstanding patent ruling. » Mais em de.investing.com


  • Liquidia Corporation: Yutrepia launch outpaces expectations, litigation likely to be resolved

    The Summers Value Fund named Liquidia Corporation a top contributor after the Yutrepia launch continued to exceed investor expectations and is expected to sustain momentum. The fund expects a near-term favorable resolution of litigation that could unlock further gains. Liquidia shares are up 141.61% over the past year (down 22.08% in the past month) and the company has a market capitalization of $6.24 billion. » Mais em finance.yahoo.com


  • Greenhaven Road Capital posts Q2 gain, trims concentration and realized short-term gain on Liquidia

    Greenhaven Road Capital reported an approximate 11% net return in Q2 2026 and said it will lower portfolio concentration, increase positions with near-term catalysts and take a more proactive approach to profit-taking. The firm emphasized continued focus on high-quality businesses and research that challenges consensus as several large holdings face near-term events. Greenhaven noted it sold a portion of its Liquidia position after a >30% pre-verdict rise, realizing a short-term gain, and will reassess the investment following the patent dispute outcome. » Mais em finance.yahoo.com


  • Liquidia Technologies rises premarket ahead of Q2 results on YUTREPIA momentum

    The stock of Liquidia Technologies rose 2.7% in premarket trading after the company announced its Q2 2026 results before the open and a management webcast at 8:30 a.m. ET. Analyst consensus expects about $165 million in revenue and $0.70 EPS, supported by a history of positive earnings surprises. Strong commercialization of YUTREPIA (over 4,500 prescriptions, about 3,750 treatment starts, conversion rate ≥85%) and recent price-target increases (including H.C. Wainwright $130, BTIG $109) are driving positive sentiment; the stock has gained about 105% since the end of March. » Mais em de.investing.com

Dados financeiros

No último trimestre, Liquidia registou receitas de € 198,91 mi e um ganho líquido de -€ 208,64 mi

(EUR) setembro de 2026
YoY
Receitas 198,91 mi 329,54%
Ganho bruto 185,86 mi 326,26%
Ganho líquido -208,64 mi 6.830,31%
EBITDA -232,17 mi 7.107,58%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 4,47 bi
Número de ações
90,11 mi
Máximo/mínimo de 52 semanas
€ 85,31 - € 20,33
Dividendos Não
Beta
0,54
PER (PE Ratio)
-52,84
PEG (PEG Ratio)
0,03
P/VC (PB Ratio)
-191,58
P/V (PS Ratio)
7,89

Perfil da empresa

A Liquidia Corporation, uma empresa biofarmacêutica, desenvolve, fabrica e comercializa diversos produtos para necessidades não satisfeitas dos doentes nos Estados Unidos. Os seus candidatos a produto incluem o YUTREPIA, uma formulação de treprostinil em pó seco para inalação, destinada ao tratamento da hipertensão arterial pulmonar. A empresa também distribui injeção de treprostinil genérico nos Estados Unidos. A Liquidia Corporation foi fundada em 2004 e tem sede em Morrisville, Carolina do Norte.

Nome
Liquidia
CEO
Roger A. Jeffs
Sede Morrisville, nc
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
26/07/2018
Colaboradores 216

Símbolos de ticker

Bolsa Símbolo
NASDAQ
LQDA
Frankfurt
LT4.F
Düsseldorf
LT4.DU
München
LT4.MU
🍪

Parqet  utiliza cookies. Saber mais